ORCIPRENALINE 2 MG
ORCIPRENALINE SULFATE : 2 MG · DIN 02236565 · APOTEX INC
Health Canada status: APPROVED
What is ORCIPRENALINE?
ORCIPRENALINE 2 MG contains ORCIPRENALINE SULFATE : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02236565, held by APOTEX INC, supplied as SYRUP for ORAL administration. Health Canada currently lists it as approved, status dated 17-Sep-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ORCIPRENALINE used for?
Bronchial asthma, chronic bronchitis, pulmonary emphysema. May be useful for bronchospasm in sarcoidosis, silicosis, carcinoma of the lung and tuberculosis. Not for acute bronchospasm.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02236565 |
|---|---|
| Brand name | ORCIPRENALINE |
| Generic / active ingredient | ORCIPRENALINE SULFATE : 2 MG |
| Manufacturer | APOTEX INC |
| Strength | 2 MG |
| Dosage form | SYRUP |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | R03CB03 ORCIPRENALINE |
| AHFS class | 12:12.08.12 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 17-Sep-2021 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02236565 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2236565 |
| Brand name | ORCIPRENALINE |
| Active ingredient / INN | ORCIPRENALINE SULFATE : 2 MG |
| ATC code | R03CB03 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R03 |
| AHFS class | 12:12.08.12 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | APOTEX INC |
How is it administered?
Adults: 20 mg (10 mL) 3-4 times daily. Adolescents (12-18): 20 mg (10 mL) 3 times daily. Children (4-12): 10 mg (5 mL) 3 times daily. Max daily dose: 80 mg. Administer orally.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at room temperature (15 - 30°C). Protect from exposure to light.
How is it supplied?
Amber-coloured bottles containing 250 mL of clear syrup.
Which pack is which?
| Strength on the label | 2 MG |
|---|---|
| Dosage form | SYRUP |
| Route | ORAL |
| Packaging as described in the monograph | Amber-coloured bottles containing 250 mL of clear syrup. |
| Storage | Store at room temperature (15 - 30°C). Protect from exposure to light. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Contraindications
Hypersensitivity to drug/ingredients; hypertrophic obstructive cardiomyopathy; cardiac arrhythmias with tachycardia; use with beta-blockers; tocolytic use in premature labour/threatened abortion.
Warnings and precautions
Not for acute/deteriorating asthma. Use with care in patients with hypertension, coronary artery disease, CHF, diabetes, glaucoma, or hyperthyroidism. Risk of serious hypokalemia and cardiac effects.
What can be used instead?
Other Canadian products sharing ATC code R03CB03 ORCIPRENALINE. 0 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALUPENT SYR 10MG/5.0ML | 10 MG / 5 ML | SYRUP | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | CANCELLED POST MARKET | DIN 00249920 |
| ALUPENT TAB 20MG | 20 MG | TABLET | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | CANCELLED POST MARKET | DIN 00003891 |
| ORCIPREN | 10 MG / 5 ML | SYRUP | TECHNILAB PHARMA INC. | CANCELLED POST MARKET | DIN 02229862 |
| ORCIPRENALINE | 2 MG | SYRUP | AA PHARMA INC | DORMANT | DIN 02236783 |
| RATIO-ORCIPRENALINE SYRUP 2MG/ML | 2 MG | SYRUP | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02152568 |
| TANTA ORCIPRENALINE SYRUP - SYR 2MG/ML | 2 MG | SYRUP | TANTA PHARMACEUTICALS INC | CANCELLED POST MARKET | DIN 02192675 |
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.